Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) rose 9.4% during trading on Thursday . The company traded as high as $11.10 and last traded at $11.21. Approximately 38,319 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 240,503 shares. The stock had previously closed at $10.25.
Wall Street Analyst Weigh In
UPB has been the topic of several research reports. Piper Sandler initiated coverage on Upstream Bio in a research report on Tuesday, November 5th. They issued an "overweight" rating and a $75.00 target price on the stock. TD Cowen started coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They issued a "buy" rating on the stock. William Blair started coverage on Upstream Bio in a research report on Tuesday, November 5th. They set an "outperform" rating for the company. Finally, JPMorgan Chase & Co. began coverage on Upstream Bio in a report on Tuesday, November 5th. They set an "overweight" rating and a $38.00 price objective on the stock.
Read Our Latest Analysis on Upstream Bio
Upstream Bio Stock Down 7.8 %
The stock's fifty day simple moving average is $16.57.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The business had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.83 million. On average, research analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.
Institutional Trading of Upstream Bio
An institutional investor recently bought a new position in Upstream Bio stock. Moody Aldrich Partners LLC acquired a new stake in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 74,773 shares of the company's stock, valued at approximately $1,229,000. Moody Aldrich Partners LLC owned about 0.14% of Upstream Bio as of its most recent filing with the SEC.
Upstream Bio Company Profile
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
